Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis/GSK Cancer Deal Gets FTC OK Based On Existing Divestments

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis’ transfer of Phase III BRAF and MEK inhibitors to partner Array BioPharma satisfies Federal Trade Commission’s anticompetitive concerns; no divestiture yet announced for GSK acquisition of Novartis [See Deal]vaccines.

You may also be interested in...



FTC Narrowly Okays AbbVie/Allergan Merger As Dissenter Slams Divestitures To AstraZeneca, Nestlé

Commissioner Chopra says candy maker Nestlé cannot take Allergans place in the market and AstraZeneca would get a windfall without paying anything for a valuable drug development project. AbbVie/Allergan must divest enzyme replacement therapies Zenpap and Viokace to Nestlé and investigational IL-23 inhibitor brazikumab to AstraZeneca. 

Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.

Array Expects To Have Phase III MEK Inhibitor All To Itself, Without Partner Novartis

Following Novartis’ oncology deal with GSK, which included another MEK inhibitor, Array anticipates getting the asset back for itself. Novartis would be obliged to continue supporting Phase III studies, Array says, as part of a pipeline update in second-quarter earnings call.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel